Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Freedom performs better with ticlopidine

This article was originally published in Clinica

Executive Summary

Global Therapeutics' Freedom stent performs poorly in calcified lesions, research carried out in the EU has shown. Dr Bernard Chevallier of the Centre Cardiologique du Nord, France, presented data from the first 530 patients treated there and in Belgium up to the beginning of March. Ten percent of patients received more than one stent - bringing the total number of implants to 633. Recoil occurred in 9.3% and technical success was 96.3%, Dr Chevallier told delegates at the ACC meeting. The 21 failures were mostly in calcified lesions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT087717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel